Germany's Merck Says Erbitux Meets Endpoints in China Phase III Trial

Merck KgaA of Germany said Erbitux met its primary endpoint in a China Phase III trial among patients with RAS wild-type metastatic colorectal cancer (mCRC). According to the company, Erbitux increased progression-free survival (PFS) significantly. Erbitux was added to FOLFOX chemotherapy and compared to FOLFOX alone. Specific data from the trial were not included in the company's release, but will be made public at an upcoming scientific meeting. More details.... Stock Symbol: (Xetra: MRK) Share this with colleagues: // //